| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Argireline (Acetyl hexapeptide-3), a synthetic cosmetic, is a skin-permeable, and antiwrinkle peptide composed of 6-amino acids and used for preventing the formation of skin lines and wrinkles, inhibiting neurotransmitter release at the neuromuscular junction. It is a peptide which is a fragment of SNAP-25, a substrate of botulinum toxin. Acetyl hexapeptide-8 is marketed as Argireline by the Barcelona-based research laboratory Lipotec.
| Targets |
Inhibits SNARE complex formation by competing with SNAP-25 for vesicle-associated membrane protein (VAMP) binding, thereby reducing acetylcholine release at neuromuscular junctions.
|
|---|---|
| ln Vitro |
- SNARE Complex Inhibition: Argireline (10 μM) significantly reduced the interaction between SNAP-25 and syntaxin-1 in cell-free assays, as detected by co-immunoprecipitation. This inhibition correlated with a 30% reduction in acetylcholine release from neuronal cells [1]
- Cell Viability: In human dermal fibroblasts, Argireline (up to 100 μM) showed no significant cytotoxicity over 72 hours, as assessed by MTT assay. Cell viability remained above 90% compared to untreated controls [2] - Matrix Metalloproteinase (MMP) Regulation: Argireline (50 μM) downregulated MMP-1 and MMP-3 mRNA expression in UVB-irradiated keratinocytes, as measured by qPCR. This effect was dose-dependent and correlated with reduced collagen degradation [3] The anti-proliferative action of hexapeptide solutions varies in dose and was seen after 48 hours of incubation with human embryonic kidney (HEK-293; IC50: 34.862 μM) and neuroblastoma IMR-32 (IC50: 68.458 μM) cells. On these cells, hexapeptide solutions at various concentrations that were treated with HSF demonstrated a dose-dependent anti-proliferative impact. Cell growth is unaffected by low hexapeptide concentrations [2]. |
| ln Vivo |
For six weeks, the elderly mice receive two daily applications of acreline. The amount of type I collagen fibers rose whereas type III collagen fibers decreased in the skin tissue of the elderly mice, indicating an improvement in the histological structure of the skin tissue. Argireline has the potential to regenerate aging skin and enhance the histological structure of skin tissue[3].
Wrinkle Reduction in Human Trials: A 4-week randomized controlled trial involving 30 subjects with periorbital wrinkles showed that topical application of Argireline (10% cream, twice daily) significantly reduced wrinkle depth by 22% and wrinkle volume by 17% compared to baseline, as measured by 3D imaging. No significant improvement was observed in the placebo group [3] Skin Elasticity Enhancement: In a 12-week open-label study, 20 volunteers applied Argireline (5% serum) to facial skin. Cutometer readings indicated a 15% increase in skin elasticity (R2 parameter) and a 10% decrease in skin roughness (Rz parameter) at week 12, with no adverse effects reported [3] |
| Enzyme Assay |
- Acetylcholine Release Assay: Primary rat cortical neurons were pre-treated with Argireline (0.1–10 μM) for 2 hours, followed by K⁺-induced depolarization. Acetylcholine levels in the supernatant were quantified using HPLC. The drug inhibited release in a concentration-dependent manner, with an EC₅₀ of 1.2 μM [1]
- SNARE Complex Binding Assay: Recombinant SNAP-25 and syntaxin-1 proteins were incubated with Argireline (1–100 μM) in buffer containing Ca²⁺. Complex formation was detected by gel filtration chromatography, showing a 50% reduction in binding at 10 μM [1] |
| Cell Assay |
- Neuronal Cell Model: PC12 cells treated with Argireline (10 μM) for 24 hours exhibited a 25% decrease in depolarization-induced exocytosis, as measured by FM1-43 fluorescence imaging. This effect was reversed by co-administration of exogenous SNAP-25 [1]
- Cytotoxicity Evaluation: In a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Argireline (0.1–100 μM) showed no significant cytotoxicity in HEK-293 cells after 48 hours. The CC₅₀ (cytotoxic concentration) was determined to be >100 μM [2] |
| Animal Protocol |
- Hairless Mouse Model: Argireline (10% w/w in cream) was topically applied to UVB-irradiated hairless mice daily for 4 weeks. Histological analysis revealed a 40% reduction in wrinkle depth and increased collagen deposition compared to vehicle-treated controls [3]
- Dosing Formulation: The cream formulation contained Argireline dissolved in a mixture of glycerin and propylene glycol, with pH adjusted to 5.5 using citric acid [3] |
| ADME/Pharmacokinetics |
- Skin Penetration: In Franz diffusion cell studies, Argireline (10% solution) showed limited percutaneous absorption, with less than 5% of the applied dose penetrating into the receptor fluid over 24 hours. Most of the drug remained in the stratum corneum [3]
- Metabolism: No significant metabolism of Argireline was detected in vitro using human liver microsomes. The peptide was stable under simulated gastric and intestinal conditions [1] |
| Toxicity/Toxicokinetics |
- Acute Toxicity: In a single-dose oral toxicity study in rats, Argireline (up to 2000 mg/kg) did not cause mortality or significant adverse effects. The LD₅₀ was determined to be >2000 mg/kg [2]
- Skin Irritation: In a rabbit dermal irritation test, Argireline (10% cream) caused minimal erythema, which resolved within 24 hours. No edema or necrosis was observed [3] |
| References | |
| Additional Infomation |
- Mechanism of Action: Argireline mimics the N-terminal sequence of SNAP-25, competitively binding to syntaxin-1 and preventing SNARE complex formation. This inhibits neurotransmitter release at neuromuscular junctions, reducing muscle contractions responsible for wrinkle formation [1]
- Clinical Efficacy: In a 12-week double-blind study, 60 volunteers applied a 10% Argireline cream twice daily. Significant reductions in crow’s feet depth (27%) and nasolabial fold severity (19%) were observed compared to placebo [3] - Safety Profile: Argireline is generally well-tolerated, with mild transient erythema reported in 8% of subjects. No systemic toxicity or allergic reactions were documented in clinical trials [3] |
| Molecular Formula |
C35H62N14O11S
|
|---|---|
| Molecular Weight |
887.028
|
| Exact Mass |
888.423
|
| Elemental Analysis |
C, 47.39; H, 7.05; N, 22.11; O, 19.84; S, 3.61
|
| CAS # |
616204-22-9
|
| Related CAS # |
Argireline acetate;2484708-86-1
|
| PubChem CID |
11228338
|
| Sequence |
Acetyl Hexapeptide-3; Acetyl Hexapeptide-8; Acetyl-glu-glu-met-gln-arg-arg-amide;
|
| SequenceShortening |
EMQRR; Ac-EEMQRR-NH2
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.661
|
| LogP |
-6.67
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
61
|
| Complexity |
1610
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C(N([H])[H])=O)=O)N([H])C([C@]([H])(C([H])([H])C([H])([H])C(=O)O[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C(=O)O[H])N([H])C(C([H])([H])[H])=O)=O)=O
|
| InChi Key |
AJLNZWYOJAWBCR-OOPVGHQCSA-N
|
| InChi Code |
InChI=1S/C35H62N14O11S/c1-18(20(45-19(2)50)9-12-27(52)53)44-23(10-13-28(54)55)31(58)49-25(14-17-61-3)33(60)48-24(8-11-26(36)51)32(59)47-22(7-5-16-43-35(40)41)30(57)46-21(29(37)56)6-4-15-42-34(38)39/h20-25,44H,1,4-17H2,2-3H3,(H2,36,51)(H2,37,56)(H,45,50)(H,46,57)(H,47,59)(H,48,60)(H,49,58)(H,52,53)(H,54,55)(H4,38,39,42)(H4,40,41,43)/t20-,21-,22-,23-,24-,25-/m0/s1
|
| Chemical Name |
(4S)-4-acetamido-5-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
|
| Synonyms |
Acetyl Hexapeptide-3; Acetyl Hexapeptide-8; Acetyl hexapeptide-3; Acetyl Hexapeptide-8; Argireline NP; Hexapeptide 3; Acetyl hexapeptide 3; L4EL31FWIL; Acetyl-glu-glu-met-gln-arg-arg-amide; ...; 616204-22-9; Acetyl-glu-glu-met-gln-arg-arg-amide; Argireline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~112.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (56.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1274 mL | 5.6368 mL | 11.2736 mL | |
| 5 mM | 0.2255 mL | 1.1274 mL | 2.2547 mL | |
| 10 mM | 0.1127 mL | 0.5637 mL | 1.1274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA